Pharmaceutical Industry In China To 2020
YRH: Pharmaceutical Industry in China to 2020 Market Overview, Size, Share,
Analysis, Technology Developments, Development Status, Trends, Structure,
Production Value and Forecast Research Report
Summary
“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese
Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints,
Opportunities & Challengess” provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:
• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN,
SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK,
NOVARTIS)
• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
• Company financials, sales & revenue figures
• China GDP, economic growth, export (bulk drug, formulations) figures
• Indian health expenditure as a function of GDP
• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain,
Japan, Canada)
• Projected figures of strategic emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics include:
• Key strengths, weaknesses and threats influencing leading player position within the market • Top Five Contract Pharmaceutical Export Markets of China
• Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
• Multinational penetration into the Chinese Pharma Market
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top Chinese pharmacos
• Economic indicators,
Analysis, Technology Developments, Development Status, Trends, Structure,
Production Value and Forecast Research Report
Summary
“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese
Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints,
Opportunities & Challengess” provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:
• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN,
SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK,
NOVARTIS)
• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
• Company financials, sales & revenue figures
• China GDP, economic growth, export (bulk drug, formulations) figures
• Indian health expenditure as a function of GDP
• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain,
Japan, Canada)
• Projected figures of strategic emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics include:
• Key strengths, weaknesses and threats influencing leading player position within the market • Top Five Contract Pharmaceutical Export Markets of China
• Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
• Multinational penetration into the Chinese Pharma Market
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top Chinese pharmacos
• Economic indicators,